Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples